- Home
- AACG vs VYNE Comparison
AACG vs VYNE Comparison
Compare AACG & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AACG
- VYNE
- Stock Information
- Founded
- AACG 1999
- VYNE 2003
- Country
- AACG China
- VYNE United States
- Employees
- AACG N/A
- VYNE N/A
- Industry
- AACG Other Consumer Services
- VYNE Biotechnology: Pharmaceutical Preparations
- Sector
- AACG Real Estate
- VYNE Health Care
- Exchange
- AACG Nasdaq
- VYNE Nasdaq
- Market Cap
- AACG 24.4M
- VYNE 24.3M
- IPO Year
- AACG N/A
- VYNE 2018
- Fundamental
- Price
- AACG $1.96
- VYNE $0.35
- Analyst Decision
- AACG
- VYNE Buy
- Analyst Count
- AACG 0
- VYNE 2
- Target Price
- AACG N/A
- VYNE $8.00
- AVG Volume (30 Days)
- AACG 690.5K
- VYNE 4.1M
- Earning Date
- AACG 08-06-2025
- VYNE 08-14-2025
- Dividend Yield
- AACG N/A
- VYNE N/A
- EPS Growth
- AACG N/A
- VYNE N/A
- EPS
- AACG N/A
- VYNE N/A
- Revenue
- AACG $39,064,701.00
- VYNE $476,000.00
- Revenue This Year
- AACG N/A
- VYNE $42.51
- Revenue Next Year
- AACG N/A
- VYNE N/A
- P/E Ratio
- AACG N/A
- VYNE N/A
- Revenue Growth
- AACG 15.19
- VYNE N/A
- 52 Week Low
- AACG $0.50
- VYNE $0.33
- 52 Week High
- AACG $2.30
- VYNE $4.30
- Technical
- Relative Strength Index (RSI)
- AACG 60.72
- VYNE 29.46
- Support Level
- AACG $1.42
- VYNE $0.35
- Resistance Level
- AACG $2.13
- VYNE $0.36
- Average True Range (ATR)
- AACG 0.38
- VYNE 0.04
- MACD
- AACG 0.04
- VYNE -0.02
- Stochastic Oscillator
- AACG 72.58
- VYNE 1.79
About AACG ATA Creativity Global
ATA Creativity Global is an international educational services company focused on providing quality learning experiences that cultivate and enhance students' creativity. The operating segments of the company are (i) Overseas art study services (ii) Other educational services and (iii) Other services. Majority of its revenue comes from Overseas art study services.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.